| Date | Time | Source | Headline | Symbol | Company |
| 02/03/2015 | 7:35AM | Business Wire | ARIAD to Present at the Leerink Global Healthcare Conference | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 02/02/2015 | 4:39PM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/30/2015 | 4:33PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/29/2015 | 7:35AM | Business Wire | ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2014 Financial Results | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/26/2015 | 4:10PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/22/2015 | 7:35AM | Business Wire | ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal & Administrative O... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/20/2015 | 1:03PM | Business Wire | ARIAD meldet endgültige Entscheidung der Europäischen Kommission mit Bestätigung der Zulassung von Iclusig für die besteh... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/20/2015 | 11:39AM | Business Wire | ARIAD annonce la décision favorable finale de la Commission Européenne concernant les indications approuvées d'Iclusig en ... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/20/2015 | 7:35AM | Business Wire | ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/15/2015 | 4:31PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/14/2015 | 6:01AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/13/2015 | 7:35AM | Business Wire | ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/07/2015 | 4:16PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/06/2015 | 1:39PM | Business Wire | ARIAD annonce le début de son essai de dosage de phase II d'Iclusig® (ponatinib) mi-2015 | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/06/2015 | 1:39PM | Business Wire | ARIAD kündigt Start einer Phase-2-Dosisfindungsstudie zu Iclusig (Ponatinib) für Mitte 2015 an | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 01/06/2015 | 7:35AM | Business Wire | ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015 | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/30/2014 | 4:18PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/30/2014 | 4:04PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/30/2014 | 9:15AM | Business Wire | ARIAD meldet Vermarktungsabkommen für Iclusig in sieben mittel- und osteuropäischen Ländern | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/30/2014 | 7:35AM | Business Wire | ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/30/2014 | 7:35AM | Business Wire | ARIAD annonce une entente de commercialisation pour l’Iclusig dans sept pays d’Europe centrale et de l’Est | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/23/2014 | 7:00AM | Business Wire | ARIAD & Otsuka Announce Co-Development & Commercialization Agreement for Iclusig to Treat Leukemias in Japan & Nine Other Asi... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/22/2014 | 7:35AM | Business Wire | ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/19/2014 | 4:29PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/18/2014 | 4:10PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/11/2014 | 4:16PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/09/2014 | 7:35AM | Business Wire | ARIAD Announces Follow-up Data from Phase 1 & PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leu... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/09/2014 | 7:35AM | Business Wire | ARIAD Announces Long-Term Safety & Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 12/08/2014 | 7:35AM | Business Wire | ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/25/2014 | 4:22PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |